PubMed

Protein C as a surrogate end-point for clinical trials of sepsis.

Liu KD, Matthay MA.

Crit Care. 2008;12(2):139. Epub 2008 Apr 24.PMID: 18492215 [PubMed - indexed for MEDLINE]Related articlesFree article

Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated).

Shorr AF, Nelson DR, Wyncoll DL, Reinhart K, Brunkhorst F, Vail GM, Janes J.

Crit Care. 2008;12(2):R45. Epub 2008 Apr 4. Review.PMID: 18394162 [PubMed - indexed for MEDLINE]Related articlesFree article

Static and dynamic assessment of biomarkers in surgical patients with severe sepsis.

Lowry SF, Awad S, Ford H, Cheadle W, Williams MD, Qualy RL, McCollam JS, Bates BM, Fry DE; PROWESS Surgical Evaluation Committee.

Surg Infect (Larchmt). 2004 Fall;5(3):261-8.PMID: 15684797 [PubMed - indexed for MEDLINE]Related articles

Clinical trials in severe sepsis with drotrecogin alfa (activated).

Laterre PF.

Crit Care. 2007;11 Suppl 5:S5. Review.PMID: 18269692 [PubMed - indexed for MEDLINE]Related articlesFree article

[Clinical approach to the identification of patients suffering from severe sepsis with several organ failures for the administration of drotrecogin alfa (activated): from the PROWESS study to clinical practice]

Dhainaut JF, Payen DM, Bernardin G, Gérard JL, Martin C, Perrotin D, Regnier B.

Ann Fr Anesth Reanim. 2003 Dec;22 Spec No 1:53-64. Review. French. No abstract available. PMID: 15359946 [PubMed - indexed for MEDLINE]Related articles

Activated protein C (Xigris) treatment in sepsis: a drug in trouble.

Gårdlund B.

Acta Anaesthesiol Scand. 2006 Sep;50(8):907-10.PMID: 16923083 [PubMed - indexed for MEDLINE]Related articles

[Surgical patients with severe sepsis: first results of the PROWESS study. Demographic data]

Montravers P, Blaise M.

Ann Fr Anesth Reanim. 2003 Dec;22 Spec No 1:38-9. French. No abstract available. PMID: 15359941 [PubMed - indexed for MEDLINE]Related articles

A retrospective observational study of drotrecogin alfa (activated) in adults with severe sepsis: comparison with a controlled clinical trial.

Wheeler A, Steingrub J, Schmidt GA, Sanchez P, Jacobi J, Linde-Zwirble W, Bates B, Qualy RL, Woodward B, Zeckel M.

Crit Care Med. 2008 Jan;36(1):14-23.PMID: 18158435 [PubMed - indexed for MEDLINE]Related articles

A blind clinical evaluation committee should, in theory, make data of a randomized clinical trial stronger, not weaker.

Carlet J.

Intensive Care Med. 2004 May;30(5):994; author reply 995. Epub 2004 Apr 9. No abstract available. PMID: 15083270 [PubMed - indexed for MEDLINE]Related articles

Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism [ISRCTN74215569].

Kinasewitz GT, Yan SB, Basson B, Comp P, Russell JA, Cariou A, Um SL, Utterback B, Laterre PF, Dhainaut JF; PROWESS Sepsis Study Group.

Crit Care. 2004 Apr;8(2):R82-90. Epub 2004 Feb 10.PMID: 15025782 [PubMed - indexed for MEDLINE]Related articlesFree article

Risks and benefits of activated protein C treatment for severe sepsis.

Warren HS, Suffredini AF, Eichacker PQ, Munford RS.

N Engl J Med. 2002 Sep 26;347(13):1027-30. No abstract available. PMID: 12324562 [PubMed - indexed for MEDLINE]Related articles

Activated protein C: beyond 28 days.

Manocha S, Walley KR.

Crit Care Med. 2004 Nov;32(11):2348-9. No abstract available. PMID: 15640656 [PubMed - indexed for MEDLINE]Related articles

Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated).

Opal SM, Garber GE, LaRosa SP, Maki DG, Freebairn RC, Kinasewitz GT, Dhainaut JF, Yan SB, Williams MD, Graham DE, Nelson DR, Levy H, Bernard GR.

Clin Infect Dis. 2003 Jul 1;37(1):50-8. Epub 2003 Jun 24.PMID: 12830408 [PubMed - indexed for MEDLINE]Related articles

How to ENHANCE our knowledge of activated protein C during pediatric sepsis trials: pediatric versus adult trials.

Hazelzet JA.

Pediatr Crit Care Med. 2006 May;7(3):277-8. No abstract available. PMID: 16682888 [PubMed - indexed for MEDLINE]Related articles

The protein C pathway: implications for the design of the RESPOND study.

Vangerow B, Shorr AF, Wyncoll D, Janes J, Nelson DR, Reinhart K.

Crit Care. 2007;11 Suppl 5:S4. Review.PMID: 18269691 [PubMed - indexed for MEDLINE]Related articlesFree article

Should we treat severe sepsis with activated protein C?

Mackillop A.

Hosp Med. 2003 May;64(5):316. No abstract available. PMID: 12789748 [PubMed - indexed for MEDLINE]Related articles

Protein C in critical illness.

Mann HJ, Short MA, Schlichting DE.

Am J Health Syst Pharm. 2009 Jun 15;66(12):1089-96. Review.PMID: 19498123 [PubMed - indexed for MEDLINE]Related articles

[Sepsis therapy -- how effective are the therapy strategies?]

Brunkhorst FM, Reinhart K.

Chirurg. 2008 Sep;79(9):877-8. German. No abstract available. PMID: 18942197 [PubMed - indexed for MEDLINE]Related articles

Activated protein C (Xigris): a drug in trouble.

Vangerow B, Mignini MA.

Acta Anaesthesiol Scand. 2007 Feb;51(2):261-2. No abstract available. PMID: 17261152 [PubMed - indexed for MEDLINE]Related articles

Reassessing recombinant human activated protein C for sepsis: time for a new randomized controlled trial.

Eichacker PQ, Danner RL, Suffredini AF, Cui X, Natanson C.

Crit Care Med. 2005 Oct;33(10):2426-8. No abstract available. PMID: 16215410 [PubMed - indexed for MEDLINE]Related articles